Is Protara Therapeutics Stock a Good Investment?
Protara Therapeutics Investment Advice | TARA |
- Examine Protara Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Protara Therapeutics' leadership team and their track record. Good management can help Protara Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Protara Therapeutics' business and its evolving consumer preferences.
- Compare Protara Therapeutics' performance and market position to its competitors. Analyze how Protara Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Protara Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Protara Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Protara Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Protara Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Protara Therapeutics Stock
Researching Protara Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.97. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protara Therapeutics recorded a loss per share of 2.59. The entity last dividend was issued on the 10th of January 2020. The firm had 1:40 split on the 10th of January 2020.
To determine if Protara Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protara Therapeutics' research are outlined below:
| Protara Therapeutics is way too risky over 90 days horizon | |
| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (37.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Protara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Protara Highlights Recent Updates and Anticipated 2025 Milestones |
Protara Therapeutics Quarterly Cash And Short Term Investments |
|
Protara Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Protara Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protara Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Protara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Protara Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-03 | 2022-09-30 | -0.76 | -0.68 | 0.08 | 10 | ||
2021-03-11 | 2020-12-31 | -0.54 | -0.44 | 0.1 | 18 | ||
2023-11-03 | 2023-09-30 | -0.98 | -0.87 | 0.11 | 11 | ||
2023-08-03 | 2023-06-30 | -0.87 | -1.0 | -0.13 | 14 | ||
2022-08-09 | 2022-06-30 | -0.94 | -0.8 | 0.14 | 14 | ||
2024-08-06 | 2024-06-30 | -0.8 | -0.45 | 0.35 | 43 | ||
2019-10-31 | 2019-09-30 | -3.6 | -3.2 | 0.4 | 11 | ||
2021-05-06 | 2021-03-31 | -0.73 | -1.2 | -0.47 | 64 |
Know Protara Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Protara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protara Therapeutics backward and forwards among themselves. Protara Therapeutics' institutional investor refers to the entity that pools money to purchase Protara Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 185.2 K | Oppenheimer & Co Inc | 2024-09-30 | 179.1 K | Geode Capital Management, Llc | 2024-09-30 | 170 K | Ikarian Capital, Llc | 2024-09-30 | 155.7 K | Two Sigma Advisers, Llc | 2024-09-30 | 151.6 K | Blackrock Inc | 2024-09-30 | 117 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 77.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 49.2 K | Lpl Financial Corp | 2024-09-30 | 46 K | Ra Capital Management, Llc | 2024-09-30 | 1.9 M | Opaleye Management Inc | 2024-09-30 | 1.7 M |
Protara Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 160.93 M.Market Cap |
|
Protara Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.68) | (0.71) |
Determining Protara Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Protara Therapeutics is a good buy. For example, gross profit margin measures Protara Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Protara Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Protara Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Protara Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Protara Therapeutics' management manipulating its earnings.
Evaluate Protara Therapeutics' management efficiency
Protara Therapeutics has return on total asset (ROA) of (0.2811) % which means that it has lost $0.2811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4591) %, meaning that it created substantial loss on money invested by shareholders. Protara Therapeutics' management efficiency ratios could be used to measure how well Protara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.72. At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 16.9 M, whereas Net Tangible Assets are forecasted to decline to about 71.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.93 | 6.59 | |
| Tangible Book Value Per Share | 6.93 | 6.59 | |
| Enterprise Value Over EBITDA | 0.27 | 0.28 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 0.27 | 0.28 | |
| Price Fair Value | 0.36 | 0.34 | |
| Enterprise Value | 14.3 M | 13.6 M |
The strategic initiatives led by Protara Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.786 |
Basic technical analysis of Protara Stock
As of the 18th of January 2025, Protara Therapeutics holds the Coefficient Of Variation of 577.85, semi deviation of 4.14, and Risk Adjusted Performance of 0.1539. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protara Therapeutics, as well as the relationship between them.Protara Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protara Therapeutics' Outstanding Corporate Bonds
Protara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protara bonds can be classified according to their maturity, which is the date when Protara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View |
Understand Protara Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Protara Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1539 | |||
| Market Risk Adjusted Performance | (20.04) | |||
| Mean Deviation | 5.87 | |||
| Semi Deviation | 4.14 | |||
| Downside Deviation | 5.32 | |||
| Coefficient Of Variation | 577.85 | |||
| Standard Deviation | 10.61 | |||
| Variance | 112.58 | |||
| Information Ratio | 0.1703 | |||
| Jensen Alpha | 1.83 | |||
| Total Risk Alpha | 1.58 | |||
| Sortino Ratio | 0.3393 | |||
| Treynor Ratio | (20.05) | |||
| Maximum Drawdown | 78.24 | |||
| Value At Risk | (7.16) | |||
| Potential Upside | 13.0 | |||
| Downside Variance | 28.35 | |||
| Semi Variance | 17.17 | |||
| Expected Short fall | (8.04) | |||
| Skewness | 4.31 | |||
| Kurtosis | 26.41 |
| Risk Adjusted Performance | 0.1539 | |||
| Market Risk Adjusted Performance | (20.04) | |||
| Mean Deviation | 5.87 | |||
| Semi Deviation | 4.14 | |||
| Downside Deviation | 5.32 | |||
| Coefficient Of Variation | 577.85 | |||
| Standard Deviation | 10.61 | |||
| Variance | 112.58 | |||
| Information Ratio | 0.1703 | |||
| Jensen Alpha | 1.83 | |||
| Total Risk Alpha | 1.58 | |||
| Sortino Ratio | 0.3393 | |||
| Treynor Ratio | (20.05) | |||
| Maximum Drawdown | 78.24 | |||
| Value At Risk | (7.16) | |||
| Potential Upside | 13.0 | |||
| Downside Variance | 28.35 | |||
| Semi Variance | 17.17 | |||
| Expected Short fall | (8.04) | |||
| Skewness | 4.31 | |||
| Kurtosis | 26.41 |
Consider Protara Therapeutics' intraday indicators
Protara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Protara Therapeutics Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 17th of December 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 11th of December 2024 Other Reports | ViewVerify |
Protara Stock media impact
Far too much social signal, news, headlines, and media speculation about Protara Therapeutics that are available to investors today. That information is available publicly through Protara media outlets and privately through word of mouth or via Protara internal channels. However, regardless of the origin, that massive amount of Protara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protara Therapeutics alpha.
Protara Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Protara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Protara Therapeutics Corporate Management
| MBA MPH | VP CoFounder | Profile | |
| Jesse Shefferman | Principal CoFounder | Profile | |
| Jathin MD | Executive Officer | Profile | |
| Justine OMalley | Senior Affairs | Profile | |
| Kristine Rosse | VP Officer | Profile | |
| Patrick MBA | Chief Officer | Profile | |
| Hannah Fry | Principal Controller | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Protara Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.